Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 36 | 2023 | 4255 | 1.680 |
Why?
|
| Benzoxazines | 13 | 2021 | 301 | 1.250 |
Why?
|
| HIV Infections | 46 | 2023 | 16715 | 1.150 |
Why?
|
| Anti-Retroviral Agents | 14 | 2023 | 1714 | 1.070 |
Why?
|
| Ritonavir | 13 | 2021 | 322 | 0.890 |
Why?
|
| Lamivudine | 12 | 2022 | 342 | 0.720 |
Why?
|
| HIV-1 | 19 | 2023 | 6939 | 0.680 |
Why?
|
| Alkynes | 13 | 2021 | 306 | 0.620 |
Why?
|
| Cyclopropanes | 13 | 2021 | 416 | 0.590 |
Why?
|
| Infectious Disease Transmission, Vertical | 8 | 2023 | 1320 | 0.520 |
Why?
|
| Pregnancy Complications, Infectious | 9 | 2023 | 2026 | 0.520 |
Why?
|
| HIV Protease Inhibitors | 6 | 2019 | 430 | 0.510 |
Why?
|
| Nevirapine | 5 | 2023 | 267 | 0.510 |
Why?
|
| Hepatitis B | 4 | 2023 | 695 | 0.470 |
Why?
|
| Antiretroviral Therapy, Highly Active | 11 | 2023 | 1872 | 0.450 |
Why?
|
| Dideoxynucleosides | 9 | 2019 | 122 | 0.420 |
Why?
|
| Viral Load | 20 | 2021 | 3300 | 0.420 |
Why?
|
| Acquired Immunodeficiency Syndrome | 8 | 2020 | 2232 | 0.420 |
Why?
|
| Suicidal Ideation | 3 | 2021 | 1246 | 0.380 |
Why?
|
| Zidovudine | 5 | 2022 | 620 | 0.350 |
Why?
|
| Hepatitis B virus | 4 | 2023 | 513 | 0.330 |
Why?
|
| Oligopeptides | 6 | 2014 | 1189 | 0.330 |
Why?
|
| CD4 Lymphocyte Count | 11 | 2023 | 2560 | 0.310 |
Why?
|
| Bone Density | 6 | 2023 | 3468 | 0.310 |
Why?
|
| Deoxycytidine | 7 | 2014 | 826 | 0.300 |
Why?
|
| Suicide | 2 | 2017 | 1474 | 0.300 |
Why?
|
| Adenine | 8 | 2014 | 936 | 0.290 |
Why?
|
| Hepatitis B, Chronic | 2 | 2023 | 393 | 0.290 |
Why?
|
| Antiviral Agents | 4 | 2019 | 2987 | 0.260 |
Why?
|
| Herpesvirus 1, Cercopithecine | 1 | 2023 | 2 | 0.240 |
Why?
|
| Breast Feeding | 3 | 2022 | 1338 | 0.240 |
Why?
|
| Hepatitis C | 1 | 2013 | 1591 | 0.230 |
Why?
|
| RNA, Viral | 11 | 2017 | 2901 | 0.220 |
Why?
|
| Pyrimidinones | 4 | 2010 | 370 | 0.210 |
Why?
|
| Pyridines | 6 | 2014 | 2825 | 0.210 |
Why?
|
| Pneumocystis carinii | 1 | 2023 | 74 | 0.210 |
Why?
|
| Carbamates | 3 | 2015 | 196 | 0.200 |
Why?
|
| Drug Combinations | 9 | 2021 | 1958 | 0.200 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2023 | 249 | 0.200 |
Why?
|
| DNA, Viral | 3 | 2023 | 2227 | 0.200 |
Why?
|
| HIV | 6 | 2023 | 1604 | 0.190 |
Why?
|
| Postpartum Period | 4 | 2021 | 1086 | 0.190 |
Why?
|
| Milk, Human | 2 | 2023 | 490 | 0.180 |
Why?
|
| Hepatitis B e Antigens | 4 | 2023 | 133 | 0.180 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 971 | 0.150 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2017 | 66 | 0.150 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2020 | 615 | 0.150 |
Why?
|
| Sulfonamides | 3 | 2015 | 1940 | 0.140 |
Why?
|
| Adult | 43 | 2022 | 214052 | 0.140 |
Why?
|
| Infant | 13 | 2023 | 35134 | 0.140 |
Why?
|
| Female | 52 | 2023 | 380193 | 0.130 |
Why?
|
| Pregnancy | 13 | 2023 | 29144 | 0.130 |
Why?
|
| Plasma | 2 | 2015 | 575 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2022 | 9955 | 0.130 |
Why?
|
| Pharmacogenetics | 2 | 2017 | 674 | 0.120 |
Why?
|
| Cystatin C | 1 | 2015 | 250 | 0.120 |
Why?
|
| Oxazines | 2 | 2005 | 298 | 0.120 |
Why?
|
| Drug Therapy, Combination | 9 | 2021 | 6489 | 0.110 |
Why?
|
| Drug Resistance, Viral | 3 | 2012 | 820 | 0.110 |
Why?
|
| Organic Anion Transporters | 1 | 2013 | 100 | 0.110 |
Why?
|
| Glucuronosyltransferase | 1 | 2012 | 128 | 0.110 |
Why?
|
| Male | 42 | 2023 | 350115 | 0.110 |
Why?
|
| Area Under Curve | 4 | 2021 | 1655 | 0.100 |
Why?
|
| Humans | 59 | 2023 | 744366 | 0.100 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 1420 | 0.100 |
Why?
|
| Treatment Failure | 5 | 2017 | 2618 | 0.100 |
Why?
|
| Proteinuria | 1 | 2014 | 658 | 0.100 |
Why?
|
| Albuminuria | 1 | 2014 | 681 | 0.090 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2011 | 138 | 0.090 |
Why?
|
| Inflammation | 3 | 2015 | 10637 | 0.090 |
Why?
|
| Child Development | 1 | 2021 | 2223 | 0.090 |
Why?
|
| Double-Blind Method | 8 | 2019 | 12025 | 0.080 |
Why?
|
| Research Design | 2 | 2022 | 5984 | 0.080 |
Why?
|
| Infant, Newborn | 7 | 2023 | 25628 | 0.080 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 1997 | 0.080 |
Why?
|
| Medication Adherence | 2 | 2017 | 2063 | 0.080 |
Why?
|
| Patient Selection | 1 | 2020 | 4216 | 0.080 |
Why?
|
| Stavudine | 2 | 2009 | 85 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2022 | 5101 | 0.070 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2007 | 65 | 0.070 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2018 | 305 | 0.070 |
Why?
|
| Hepatitis B Vaccines | 2 | 2018 | 194 | 0.070 |
Why?
|
| Gestational Age | 3 | 2020 | 3493 | 0.070 |
Why?
|
| Suicide, Attempted | 1 | 2014 | 1218 | 0.070 |
Why?
|
| Absorptiometry, Photon | 3 | 2021 | 1725 | 0.070 |
Why?
|
| Middle Aged | 23 | 2019 | 213390 | 0.070 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2005 | 115 | 0.060 |
Why?
|
| Drug Monitoring | 1 | 2011 | 956 | 0.060 |
Why?
|
| Furans | 3 | 2015 | 194 | 0.060 |
Why?
|
| Alanine Transaminase | 2 | 2018 | 592 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 257 | 0.060 |
Why?
|
| Body Composition | 1 | 2013 | 2402 | 0.060 |
Why?
|
| Cause of Death | 1 | 2014 | 3582 | 0.060 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 2703 | 0.060 |
Why?
|
| Zalcitabine | 1 | 2002 | 42 | 0.060 |
Why?
|
| Mutation, Missense | 1 | 2012 | 2566 | 0.060 |
Why?
|
| Young Adult | 11 | 2021 | 56429 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2014 | 2897 | 0.050 |
Why?
|
| Didanosine | 1 | 2002 | 153 | 0.050 |
Why?
|
| RNA | 2 | 2023 | 2749 | 0.050 |
Why?
|
| Cytokines | 1 | 2017 | 7323 | 0.050 |
Why?
|
| Body Weight | 1 | 2013 | 4671 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2012 | 3203 | 0.050 |
Why?
|
| Viremia | 2 | 2021 | 736 | 0.050 |
Why?
|
| Receptors, CXCR4 | 1 | 2007 | 727 | 0.050 |
Why?
|
| Fractures, Bone | 2 | 2011 | 1947 | 0.050 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2006 | 657 | 0.050 |
Why?
|
| Depression | 1 | 2021 | 7759 | 0.050 |
Why?
|
| Osteoporosis | 1 | 2011 | 1579 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2006 | 733 | 0.050 |
Why?
|
| Adolescent | 12 | 2020 | 85779 | 0.050 |
Why?
|
| Treatment Outcome | 8 | 2017 | 63107 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 4424 | 0.050 |
Why?
|
| Administration, Oral | 3 | 2018 | 3914 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2013 | 10252 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 3778 | 0.050 |
Why?
|
| Lumbar Vertebrae | 2 | 2023 | 1848 | 0.050 |
Why?
|
| Central Nervous System Diseases | 1 | 2004 | 518 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2014 | 6254 | 0.040 |
Why?
|
| Parturition | 1 | 2023 | 441 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 2006 | 820 | 0.040 |
Why?
|
| Phosphates | 1 | 2022 | 785 | 0.040 |
Why?
|
| Pregnant Women | 1 | 2023 | 568 | 0.040 |
Why?
|
| Infant Formula | 1 | 2020 | 199 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2021 | 724 | 0.040 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 12356 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 7914 | 0.040 |
Why?
|
| Mothers | 2 | 2020 | 2165 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2005 | 4328 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2021 | 976 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 39052 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2021 | 599 | 0.040 |
Why?
|
| Drug Interactions | 2 | 2015 | 1460 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2022 | 1608 | 0.030 |
Why?
|
| Thailand | 1 | 2016 | 296 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 12244 | 0.030 |
Why?
|
| Half-Life | 2 | 2007 | 661 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 1157 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2014 | 380 | 0.030 |
Why?
|
| Genotype | 3 | 2017 | 12952 | 0.030 |
Why?
|
| Health Resources | 1 | 2020 | 911 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2016 | 881 | 0.030 |
Why?
|
| Pelvic Bones | 1 | 2015 | 265 | 0.030 |
Why?
|
| Consensus | 1 | 2022 | 2960 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2013 | 356 | 0.030 |
Why?
|
| Jaundice | 1 | 2012 | 89 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2020 | 53290 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 1637 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2022 | 2795 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2022 | 2716 | 0.030 |
Why?
|
| Cohort Studies | 4 | 2021 | 40559 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 639 | 0.020 |
Why?
|
| Bilirubin | 1 | 2012 | 425 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2017 | 3587 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2013 | 537 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 426 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2011 | 244 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2023 | 41005 | 0.020 |
Why?
|
| Therapeutic Equivalency | 1 | 2009 | 141 | 0.020 |
Why?
|
| Child | 3 | 2023 | 77709 | 0.020 |
Why?
|
| DNA | 1 | 2023 | 7294 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2021 | 2838 | 0.020 |
Why?
|
| Calcium | 1 | 2022 | 5755 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 1793 | 0.020 |
Why?
|
| Butylamines | 1 | 2007 | 8 | 0.020 |
Why?
|
| Kidney | 1 | 2023 | 7184 | 0.020 |
Why?
|
| Aminoquinolines | 1 | 2007 | 109 | 0.020 |
Why?
|
| Self Report | 1 | 2017 | 3553 | 0.020 |
Why?
|
| Disease Progression | 1 | 2002 | 13286 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 10943 | 0.020 |
Why?
|
| Time Factors | 3 | 2014 | 40075 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2022 | 21748 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 5953 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2014 | 2585 | 0.010 |
Why?
|
| Incidence | 1 | 2021 | 20952 | 0.010 |
Why?
|
| Models, Biological | 1 | 2019 | 9584 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2004 | 419 | 0.010 |
Why?
|
| Prognosis | 1 | 2002 | 29060 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 4933 | 0.010 |
Why?
|
| Benzimidazoles | 1 | 2007 | 850 | 0.010 |
Why?
|
| Fasting | 1 | 2007 | 1592 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2009 | 6366 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6539 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 1677 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2011 | 2684 | 0.010 |
Why?
|
| United States | 2 | 2021 | 69872 | 0.010 |
Why?
|
| Sex Factors | 1 | 2013 | 10400 | 0.010 |
Why?
|
| Headache | 1 | 2007 | 1226 | 0.010 |
Why?
|
| Aged | 3 | 2021 | 163288 | 0.010 |
Why?
|
| Leukocytes | 1 | 2007 | 2045 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2005 | 1275 | 0.010 |
Why?
|
| Age Factors | 1 | 2015 | 18373 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 15520 | 0.010 |
Why?
|
| Risk Factors | 2 | 2017 | 72296 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2012 | 6542 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2006 | 3207 | 0.010 |
Why?
|
| Logistic Models | 1 | 2011 | 13409 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2006 | 4386 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 4479 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 20130 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 57776 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2009 | 77460 | 0.000 |
Why?
|
Concepts
(202)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(19)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_